Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019474 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00019474 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 60 participants.
The verdict
NCT00019474, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person recover from the side effects of chemotherapy. Combining chemotherapy with interferon alfa may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and interferon alfa followed by filgrastim in treating patients who have gastrointestinal tract cancer.
Interventions
- DRUG fluorouracil
- BIOLOGICAL filgrastim
- BIOLOGICAL recombinant interferon alfa
- DRUG hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1998-03 |
| Est. Completion | 2000-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019474
The ClinicalTrials.gov registry entry for NCT00019474 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00019474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019474 about?
NCT00019474 is a clinical study titled "Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or periphe...
What is the current status of trial NCT00019474?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1998-03. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00019474?
The interventions under investigation include: fluorouracil (DRUG), filgrastim (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00019474?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.